Physician profile
Avram Derrow
NPI 1972829125
$2,604.97
in general payments reported to CMS, 2019-2025
20 companies · $834 in 2025
The $834 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $551 · 2022: $479 · 2023: $266 · 2024: $475 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,375 · Consulting Fee: $110 · Education: $88.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,375.24 |
| Consulting Fee | $110.02 |
| Education | $88.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $659.85 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $490.84 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $265.75 | 2021-2025 | Dupixent |
| Csl Behring | $171.40 | 2023-2025 | Hizentra, Haegarda, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $132.83 | 2021-2024 | Eohilia |
| Genentech USA, INC. | $114.24 | 2022-2024 | Xolair |
| Adma Biomanufacturing LLC | $110.02 | 2023-2025 | |
| Genzyme Corporation | $91.29 | 2023-2025 | |
| Grifols USA, LLC | $87.62 | 2023-2025 | Xembify |
| Amgen INC. | $84.53 | 2022-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $63.76 | 2024-2025 | Orladeyo |
| Blueprint Medicines Corporation | $60.95 | 2024-2025 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $54.95 | 2023 | |
| Phadia US INC. | $39.20 | 2024-2025 | Immunocap |
| Gc Biopharma USA, INC. | $37.23 | 2025 | Alyglo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $32.45 | 2025 | |
| Verona Pharma, INC. | $30.75 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $30.37 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $24.00 | 2025 | Neffy |
| Greer Laboratories, INC. | $22.94 | 2025 | Oralair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avram Derrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.